Livingston Securities announces the agenda for the 2nd Annual Livingston Healthcare Summit.

Today, Scott Livingston, CEO and Founder of Livingston Securities (www.livingstonsecurities.com) announced the agenda for the 2nd Annual Livingston Healthcare and Life Science Stakeholders Summit.

The Summit is being held at:

Lighthouse International www.lhiconferencecenter.com 111 East 59th Street New York, NY 10022 212-821-9220

Conference Chair, Mostafa Analoui, PhD, Head of Healthcare and Life Sciences at Livingston Securities, said, "This is a unique and by invitation-only conference that brings together key stakeholders from pharmaceutical, capital investment, business strategy and federal science and regulatory segments. This conference will include three topics, which are among the top global issues for investors currently." Attendance in the conference is limited to assure open and interactive dialogue among participants during the sessions and networking breaks. This is intended to collectively identify key trends, as well as mutual opportunities among participants for deal making.

Invitees include CEOs, CFOs, COOs for a broad range of pharmaceutical, diagnostic, and platform technology companies, a select number of US and International VCs and PEs, along with key policy makers and federal science and regulatory agencies.

TO REGISTER please email Jonathan Mason [email protected] or call 212-520-8479.

PROGRAM OUTLINE 12:30-5:00pm

INTRODUCTION: Overview and key investment indicators, Mostafa Analoui

SESSION I: Drug Discovery and Development: Early to Mid-Stage Fund Raise and Alliance

-- BJ Bormann, PhD, SVP of Bus Dev & Licensing, Boehringer Ingelheim Pharmaceutical -- Tory Ramaker, Corporate Head of BD, Baxter -- Bill Burkoth, Director of Venture Capital, Pfizer Inc -- Misti Ushio, PhD, VP of Harris & Harris Group -- Eugene Seymour, MD, CEO of Nanoviricides, Inc

SESSION II: Diagnostics: Valuation and Future Directions

-- Mark Dente, MD, VP Healthcare Solution at GE Healthcare -- Gary Fletcher, PhD, Technology R&D, Becton-Dickenson (BD) Diagnostics -- Jonathan White, MD, Head of R&D at Haemonetics -- Douglas Fambrough, MD, Managing Partner, Oxford Bioscience Partners

SESSION III: Global and Emerging Investment Opportunities

-- Michael Nowak, PhD, Yorkville Partners -- Alex Engels, PhD, VP BD Development, Global Medication Delivery, Baxter -- Camilla khevenhueller Borghese, President of ibi, Rome, Italy -- Drs. Shamsi and Parasanna, Acunova Life Sciences, Inc

NETWORKING RECEPTION 5:00-6:00pm

"Scott Livingston's debut conference focusing on Healthcare, Life Science and Nanotechnology was a tremendous success last year," said Vincent Caprio, Vice President and Event Director, NanoBusiness Alliance. "I'm pleased to be working with Scott again this year for his second annual event, which will prove to be of even greater value to all participants and key stakeholders."